When the mail-in ancestry company 23andMe filed for bankruptcy, Regeneron Pharmaceuticals stepped in to snap it up. Though in the end the Tarrytown-based company was outbid, the scenario raised a ...

-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday. WHY ...

The 23andMe Research Institute bought the company's assets for $305 million, scotching a proposed sale to Regeneron ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said that ...

Anne Wojcicki, the co-founder and former CEO of 23andMe, has regained control over the embattled genetic testing company after her new nonprofit, TTAM Research Institute, outbid Regeneron ...

A judge has finally approved the bankruptcy sale of 23andme, and its data, to a nonprofit owned by 23andme's founder. That means that if you have data stored with the site, it's basically staying in ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a non-profit led by the company’s co-founder and former CEO Anne Wojcicki proposed ...

New York and other states filed a lawsuit seeking to block 23andMe, the bankrupt genetic testing firm, from selling millions of Americans' genetic data to the highest bidder. A total of 28 state ...

A bankruptcy judge approved the sale of genetics company 23andMe to a non-profit led by co-founder and former CEO Anne Wojcicki, according to a June 27 filing in the bankruptcy docket. TTAM Research ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, Inc. tops our list for being one of the most undervalued healthcare stocks ...